Global Highly Pathogenic PRRS Live Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Highly Pathogenic PRRS Live Vaccine market size was valued at US$ 15.43 million in 2025 and is forecast to a readjusted size of US$ 20.43 million by 2032 with a CAGR of 4.1% during review period.
Highly Pathogenic PRRS Live Vaccine is a modified live swine vaccine used for the prevention of highly pathogenic porcine reproductive and respiratory syndrome, also known as highly pathogenic porcine blue ear disease in China. Major commercial forms include monovalent vaccines based on JXA1-R, TJM-F92, GDr180, HuN4-F112 and related attenuated strains, as well as limited combination vaccines and heat-stabilized formulations containing a highly pathogenic PRRS component. Upstream inputs mainly include attenuated PRRSV seed strains, Marc-145 cells or other suitable cell substrates, culture media, serum or serum-free supplements, stabilizers, lyophilization protectants, diluents, glass vials, rubber stoppers, aluminum caps, labels and cold-chain packaging materials. Downstream customers mainly include integrated swine farming groups, breeding farms, commercial pig farms, veterinary drug distributors, animal disease control institutions and farm technical service providers. In 2025, global production capacity is estimated at around 286 million doses, with sales volume of about 207 million doses and an average ex-factory price of approximately USD 0.070–0.081 per dose; China accounts for the dominant share of both supply and demand, while overseas sales are limited and mainly related to export registration and use in nearby swine-producing markets. This is an approval- and batch-release-driven veterinary biologics segment with a relatively small single-product market size but strong disease-control relevance for pig farms. The estimated industry gross margin in 2025 is around 45%–60%, with leading producers benefiting from larger batch scale, established distribution channels and strain resources, while smaller suppliers face greater margin volatility due to batch size, channel discounts and cold-chain costs.
The current market is mainly supported by disease prevention demand in China's swine farming sector, with supply concentrated among companies that have veterinary biologics manufacturing qualifications, stable batch-release capabilities, mature cell culture processes and strong service capabilities for large-scale pig farms. This is not a globally widespread mass-market vaccine category, but a product segment closely linked to China's highly pathogenic porcine blue ear disease control system, veterinary drug registration framework and practical immunization programs in commercial swine production. Competition is not driven only by price and distribution channels, but also by product safety, batch consistency, field application experience, cold-chain assurance and the supplier's ability to support vaccination programs for farms with different herd health statuses. Demand shows clear structural differentiation. Large-scale pig farming groups and breeding farms place more emphasis on immunization safety, product consistency, strain relevance and long-term supply stability, so their purchasing decisions are generally more cautious. Commercial pig farms and small to medium-sized producers rely more on distributors, regional veterinary service networks and local disease pressure, and are relatively more price-sensitive. As swine farming becomes more consolidated, vaccine suppliers need to move beyond simple product sales and provide vaccination program design, antibody monitoring, herd stabilization management and integrated disease-control advice to strengthen customer stickiness and product value. Future development will focus more on safety improvement, process upgrading, combination vaccines and precision immunization. Traditional modified live vaccines still have advantages in immunogenicity, accumulated field experience and end-user acceptance, but their use will become more cautious in high-health-status farms and production systems pursuing PRRS elimination. Suspension culture can help improve production consistency and scale-up efficiency, heat-stabilized formulations can enhance storage and transportation stability, and combination vaccines can simplify immunization programs. As circulating PRRSV strains continue to evolve, companies also need stronger epidemiological monitoring and clinical validation capabilities to support product iteration and differentiated competition. The main growth drivers include the rising share of large-scale farming, continued investment in major swine disease control, more standardized veterinary vaccine regulation, improvement in farm biosecurity systems and stronger service capabilities among leading suppliers. Key constraints include hog price cycles affecting vaccination budgets, reduced use of live vaccines in some farms pursuing disease elimination, safety concerns related to modified live vaccines, uncertainty in protection caused by regional strain differences, and cost pressure from cold-chain logistics and batch quality control. Overall, this market is more stable and structurally adjusting than high-growth. Future growth will depend less on capacity expansion and more on product quality upgrades, customer concentration and stronger integrated service capabilities among leading companies.
This report is a detailed and comprehensive analysis for global Highly Pathogenic PRRS Live Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Highly Pathogenic PRRS Live Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Highly Pathogenic PRRS Live Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Highly Pathogenic PRRS Live Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Highly Pathogenic PRRS Live Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Highly Pathogenic PRRS Live Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Highly Pathogenic PRRS Live Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Highly Pathogenic PRRS Live Vaccine, with price, sales quantity, revenue, and global market share of Highly Pathogenic PRRS Live Vaccine from 2021 to 2026.
Chapter 3, the Highly Pathogenic PRRS Live Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Highly Pathogenic PRRS Live Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Highly Pathogenic PRRS Live Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Highly Pathogenic PRRS Live Vaccine.
Chapter 14 and 15, to describe Highly Pathogenic PRRS Live Vaccine sales channel, distributors, customers, research findings and conclusion.
Highly Pathogenic PRRS Live Vaccine is a modified live swine vaccine used for the prevention of highly pathogenic porcine reproductive and respiratory syndrome, also known as highly pathogenic porcine blue ear disease in China. Major commercial forms include monovalent vaccines based on JXA1-R, TJM-F92, GDr180, HuN4-F112 and related attenuated strains, as well as limited combination vaccines and heat-stabilized formulations containing a highly pathogenic PRRS component. Upstream inputs mainly include attenuated PRRSV seed strains, Marc-145 cells or other suitable cell substrates, culture media, serum or serum-free supplements, stabilizers, lyophilization protectants, diluents, glass vials, rubber stoppers, aluminum caps, labels and cold-chain packaging materials. Downstream customers mainly include integrated swine farming groups, breeding farms, commercial pig farms, veterinary drug distributors, animal disease control institutions and farm technical service providers. In 2025, global production capacity is estimated at around 286 million doses, with sales volume of about 207 million doses and an average ex-factory price of approximately USD 0.070–0.081 per dose; China accounts for the dominant share of both supply and demand, while overseas sales are limited and mainly related to export registration and use in nearby swine-producing markets. This is an approval- and batch-release-driven veterinary biologics segment with a relatively small single-product market size but strong disease-control relevance for pig farms. The estimated industry gross margin in 2025 is around 45%–60%, with leading producers benefiting from larger batch scale, established distribution channels and strain resources, while smaller suppliers face greater margin volatility due to batch size, channel discounts and cold-chain costs.
The current market is mainly supported by disease prevention demand in China's swine farming sector, with supply concentrated among companies that have veterinary biologics manufacturing qualifications, stable batch-release capabilities, mature cell culture processes and strong service capabilities for large-scale pig farms. This is not a globally widespread mass-market vaccine category, but a product segment closely linked to China's highly pathogenic porcine blue ear disease control system, veterinary drug registration framework and practical immunization programs in commercial swine production. Competition is not driven only by price and distribution channels, but also by product safety, batch consistency, field application experience, cold-chain assurance and the supplier's ability to support vaccination programs for farms with different herd health statuses. Demand shows clear structural differentiation. Large-scale pig farming groups and breeding farms place more emphasis on immunization safety, product consistency, strain relevance and long-term supply stability, so their purchasing decisions are generally more cautious. Commercial pig farms and small to medium-sized producers rely more on distributors, regional veterinary service networks and local disease pressure, and are relatively more price-sensitive. As swine farming becomes more consolidated, vaccine suppliers need to move beyond simple product sales and provide vaccination program design, antibody monitoring, herd stabilization management and integrated disease-control advice to strengthen customer stickiness and product value. Future development will focus more on safety improvement, process upgrading, combination vaccines and precision immunization. Traditional modified live vaccines still have advantages in immunogenicity, accumulated field experience and end-user acceptance, but their use will become more cautious in high-health-status farms and production systems pursuing PRRS elimination. Suspension culture can help improve production consistency and scale-up efficiency, heat-stabilized formulations can enhance storage and transportation stability, and combination vaccines can simplify immunization programs. As circulating PRRSV strains continue to evolve, companies also need stronger epidemiological monitoring and clinical validation capabilities to support product iteration and differentiated competition. The main growth drivers include the rising share of large-scale farming, continued investment in major swine disease control, more standardized veterinary vaccine regulation, improvement in farm biosecurity systems and stronger service capabilities among leading suppliers. Key constraints include hog price cycles affecting vaccination budgets, reduced use of live vaccines in some farms pursuing disease elimination, safety concerns related to modified live vaccines, uncertainty in protection caused by regional strain differences, and cost pressure from cold-chain logistics and batch quality control. Overall, this market is more stable and structurally adjusting than high-growth. Future growth will depend less on capacity expansion and more on product quality upgrades, customer concentration and stronger integrated service capabilities among leading companies.
This report is a detailed and comprehensive analysis for global Highly Pathogenic PRRS Live Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Highly Pathogenic PRRS Live Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Highly Pathogenic PRRS Live Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Highly Pathogenic PRRS Live Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Highly Pathogenic PRRS Live Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Highly Pathogenic PRRS Live Vaccine
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Highly Pathogenic PRRS Live Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- JXA1-R Strain Live Vaccine
- TJM-F92 Strain Live Vaccine
- GDr180 Strain Live Vaccine
- Others
- Monovalent Live Vaccine
- Combination Live Vaccine
- Small Pack (Below 20 Doses per Vial)
- Medium Pack (20–50 Doses per Vial)
- Large Pack (Above 50 Doses per Vial)
- Large-scale Integrated Pig Farming Groups
- Breeding and Multiplier Farms
- Animal Disease Control Institutions
- Others
- Dahuanong Animal Health
- Zoetis
- Jilin Teyan Biotechnology
- Qingdao Yebio Bioengineering
- Sinopharm Yangzhou Vac Biological Engineering
- Pulike Biological Engineering
- Guangdong WINSUN Bio-pharmaceutical
- Sinovetah Biological Pharmaceutical
- TECON Pharmaceutical
- Harbin Veken Biotechnology
- CAHIC
- Huapai Biotechnology Group
- Chengdu Shiji Biological Pharmaceutical
- Jilin Heyuan Biotechnology
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Highly Pathogenic PRRS Live Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Highly Pathogenic PRRS Live Vaccine, with price, sales quantity, revenue, and global market share of Highly Pathogenic PRRS Live Vaccine from 2021 to 2026.
Chapter 3, the Highly Pathogenic PRRS Live Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Highly Pathogenic PRRS Live Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Highly Pathogenic PRRS Live Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Highly Pathogenic PRRS Live Vaccine.
Chapter 14 and 15, to describe Highly Pathogenic PRRS Live Vaccine sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 JXA1-R Strain Live Vaccine
1.3.3 TJM-F92 Strain Live Vaccine
1.3.4 GDr180 Strain Live Vaccine
1.3.5 Others
1.4 Market Analysis by Product Combination
1.4.1 Overview: Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Product Combination: 2021 Versus 2025 Versus 2032
1.4.2 Monovalent Live Vaccine
1.4.3 Combination Live Vaccine
1.5 Market Analysis by Dose Pack Size
1.5.1 Overview: Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Dose Pack Size: 2021 Versus 2025 Versus 2032
1.5.2 Small Pack (Below 20 Doses per Vial)
1.5.3 Medium Pack (20–50 Doses per Vial)
1.5.4 Large Pack (Above 50 Doses per Vial)
1.6 Market Analysis by Application
1.6.1 Overview: Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 Large-scale Integrated Pig Farming Groups
1.6.3 Breeding and Multiplier Farms
1.6.4 Animal Disease Control Institutions
1.6.5 Others
1.7 Global Highly Pathogenic PRRS Live Vaccine Market Size & Forecast
1.7.1 Global Highly Pathogenic PRRS Live Vaccine Consumption Value (2021 & 2025 & 2032)
1.7.2 Global Highly Pathogenic PRRS Live Vaccine Sales Quantity (2021-2032)
1.7.3 Global Highly Pathogenic PRRS Live Vaccine Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Dahuanong Animal Health
2.1.1 Dahuanong Animal Health Details
2.1.2 Dahuanong Animal Health Major Business
2.1.3 Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Product and Services
2.1.4 Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Dahuanong Animal Health Recent Developments/Updates
2.2 Zoetis
2.2.1 Zoetis Details
2.2.2 Zoetis Major Business
2.2.3 Zoetis Highly Pathogenic PRRS Live Vaccine Product and Services
2.2.4 Zoetis Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Zoetis Recent Developments/Updates
2.3 Jilin Teyan Biotechnology
2.3.1 Jilin Teyan Biotechnology Details
2.3.2 Jilin Teyan Biotechnology Major Business
2.3.3 Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
2.3.4 Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Jilin Teyan Biotechnology Recent Developments/Updates
2.4 Qingdao Yebio Bioengineering
2.4.1 Qingdao Yebio Bioengineering Details
2.4.2 Qingdao Yebio Bioengineering Major Business
2.4.3 Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Product and Services
2.4.4 Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Qingdao Yebio Bioengineering Recent Developments/Updates
2.5 Sinopharm Yangzhou Vac Biological Engineering
2.5.1 Sinopharm Yangzhou Vac Biological Engineering Details
2.5.2 Sinopharm Yangzhou Vac Biological Engineering Major Business
2.5.3 Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Product and Services
2.5.4 Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Sinopharm Yangzhou Vac Biological Engineering Recent Developments/Updates
2.6 Pulike Biological Engineering
2.6.1 Pulike Biological Engineering Details
2.6.2 Pulike Biological Engineering Major Business
2.6.3 Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Product and Services
2.6.4 Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Pulike Biological Engineering Recent Developments/Updates
2.7 Guangdong WINSUN Bio-pharmaceutical
2.7.1 Guangdong WINSUN Bio-pharmaceutical Details
2.7.2 Guangdong WINSUN Bio-pharmaceutical Major Business
2.7.3 Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
2.7.4 Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Guangdong WINSUN Bio-pharmaceutical Recent Developments/Updates
2.8 Sinovetah Biological Pharmaceutical
2.8.1 Sinovetah Biological Pharmaceutical Details
2.8.2 Sinovetah Biological Pharmaceutical Major Business
2.8.3 Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
2.8.4 Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Sinovetah Biological Pharmaceutical Recent Developments/Updates
2.9 TECON Pharmaceutical
2.9.1 TECON Pharmaceutical Details
2.9.2 TECON Pharmaceutical Major Business
2.9.3 TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
2.9.4 TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 TECON Pharmaceutical Recent Developments/Updates
2.10 Harbin Veken Biotechnology
2.10.1 Harbin Veken Biotechnology Details
2.10.2 Harbin Veken Biotechnology Major Business
2.10.3 Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
2.10.4 Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Harbin Veken Biotechnology Recent Developments/Updates
2.11 CAHIC
2.11.1 CAHIC Details
2.11.2 CAHIC Major Business
2.11.3 CAHIC Highly Pathogenic PRRS Live Vaccine Product and Services
2.11.4 CAHIC Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 CAHIC Recent Developments/Updates
2.12 Huapai Biotechnology Group
2.12.1 Huapai Biotechnology Group Details
2.12.2 Huapai Biotechnology Group Major Business
2.12.3 Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Product and Services
2.12.4 Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Huapai Biotechnology Group Recent Developments/Updates
2.13 Chengdu Shiji Biological Pharmaceutical
2.13.1 Chengdu Shiji Biological Pharmaceutical Details
2.13.2 Chengdu Shiji Biological Pharmaceutical Major Business
2.13.3 Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
2.13.4 Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Chengdu Shiji Biological Pharmaceutical Recent Developments/Updates
2.14 Jilin Heyuan Biotechnology
2.14.1 Jilin Heyuan Biotechnology Details
2.14.2 Jilin Heyuan Biotechnology Major Business
2.14.3 Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
2.14.4 Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Jilin Heyuan Biotechnology Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: HIGHLY PATHOGENIC PRRS LIVE VACCINE BY MANUFACTURER
3.1 Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Manufacturer (2021-2026)
3.2 Global Highly Pathogenic PRRS Live Vaccine Revenue by Manufacturer (2021-2026)
3.3 Global Highly Pathogenic PRRS Live Vaccine Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Highly Pathogenic PRRS Live Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Highly Pathogenic PRRS Live Vaccine Manufacturer Market Share in 2025
3.4.3 Top 6 Highly Pathogenic PRRS Live Vaccine Manufacturer Market Share in 2025
3.5 Highly Pathogenic PRRS Live Vaccine Market: Overall Company Footprint Analysis
3.5.1 Highly Pathogenic PRRS Live Vaccine Market: Region Footprint
3.5.2 Highly Pathogenic PRRS Live Vaccine Market: Company Product Type Footprint
3.5.3 Highly Pathogenic PRRS Live Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Highly Pathogenic PRRS Live Vaccine Market Size by Region
4.1.1 Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Region (2021-2032)
4.1.2 Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Region (2021-2032)
4.1.3 Global Highly Pathogenic PRRS Live Vaccine Average Price by Region (2021-2032)
4.2 North America Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032)
4.3 Europe Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032)
4.4 Asia-Pacific Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032)
4.5 South America Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032)
4.6 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2032)
5.2 Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Type (2021-2032)
5.3 Global Highly Pathogenic PRRS Live Vaccine Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2032)
6.2 Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Application (2021-2032)
6.3 Global Highly Pathogenic PRRS Live Vaccine Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2032)
7.2 North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2032)
7.3 North America Highly Pathogenic PRRS Live Vaccine Market Size by Country
7.3.1 North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2021-2032)
7.3.2 North America Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2032)
8.2 Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2032)
8.3 Europe Highly Pathogenic PRRS Live Vaccine Market Size by Country
8.3.1 Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2021-2032)
8.3.2 Europe Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Highly Pathogenic PRRS Live Vaccine Market Size by Region
9.3.1 Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Highly Pathogenic PRRS Live Vaccine Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2032)
10.2 South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2032)
10.3 South America Highly Pathogenic PRRS Live Vaccine Market Size by Country
10.3.1 South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2021-2032)
10.3.2 South America Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Market Size by Country
11.3.1 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Highly Pathogenic PRRS Live Vaccine Market Drivers
12.2 Highly Pathogenic PRRS Live Vaccine Market Restraints
12.3 Highly Pathogenic PRRS Live Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Highly Pathogenic PRRS Live Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Highly Pathogenic PRRS Live Vaccine
13.3 Highly Pathogenic PRRS Live Vaccine Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Highly Pathogenic PRRS Live Vaccine Typical Distributors
14.3 Highly Pathogenic PRRS Live Vaccine Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Type: 2021 Versus 2025 Versus 2032
1.3.2 JXA1-R Strain Live Vaccine
1.3.3 TJM-F92 Strain Live Vaccine
1.3.4 GDr180 Strain Live Vaccine
1.3.5 Others
1.4 Market Analysis by Product Combination
1.4.1 Overview: Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Product Combination: 2021 Versus 2025 Versus 2032
1.4.2 Monovalent Live Vaccine
1.4.3 Combination Live Vaccine
1.5 Market Analysis by Dose Pack Size
1.5.1 Overview: Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Dose Pack Size: 2021 Versus 2025 Versus 2032
1.5.2 Small Pack (Below 20 Doses per Vial)
1.5.3 Medium Pack (20–50 Doses per Vial)
1.5.4 Large Pack (Above 50 Doses per Vial)
1.6 Market Analysis by Application
1.6.1 Overview: Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Application: 2021 Versus 2025 Versus 2032
1.6.2 Large-scale Integrated Pig Farming Groups
1.6.3 Breeding and Multiplier Farms
1.6.4 Animal Disease Control Institutions
1.6.5 Others
1.7 Global Highly Pathogenic PRRS Live Vaccine Market Size & Forecast
1.7.1 Global Highly Pathogenic PRRS Live Vaccine Consumption Value (2021 & 2025 & 2032)
1.7.2 Global Highly Pathogenic PRRS Live Vaccine Sales Quantity (2021-2032)
1.7.3 Global Highly Pathogenic PRRS Live Vaccine Average Price (2021-2032)
2 MANUFACTURERS PROFILES
2.1 Dahuanong Animal Health
2.1.1 Dahuanong Animal Health Details
2.1.2 Dahuanong Animal Health Major Business
2.1.3 Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Product and Services
2.1.4 Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Dahuanong Animal Health Recent Developments/Updates
2.2 Zoetis
2.2.1 Zoetis Details
2.2.2 Zoetis Major Business
2.2.3 Zoetis Highly Pathogenic PRRS Live Vaccine Product and Services
2.2.4 Zoetis Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Zoetis Recent Developments/Updates
2.3 Jilin Teyan Biotechnology
2.3.1 Jilin Teyan Biotechnology Details
2.3.2 Jilin Teyan Biotechnology Major Business
2.3.3 Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
2.3.4 Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 Jilin Teyan Biotechnology Recent Developments/Updates
2.4 Qingdao Yebio Bioengineering
2.4.1 Qingdao Yebio Bioengineering Details
2.4.2 Qingdao Yebio Bioengineering Major Business
2.4.3 Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Product and Services
2.4.4 Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 Qingdao Yebio Bioengineering Recent Developments/Updates
2.5 Sinopharm Yangzhou Vac Biological Engineering
2.5.1 Sinopharm Yangzhou Vac Biological Engineering Details
2.5.2 Sinopharm Yangzhou Vac Biological Engineering Major Business
2.5.3 Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Product and Services
2.5.4 Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Sinopharm Yangzhou Vac Biological Engineering Recent Developments/Updates
2.6 Pulike Biological Engineering
2.6.1 Pulike Biological Engineering Details
2.6.2 Pulike Biological Engineering Major Business
2.6.3 Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Product and Services
2.6.4 Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Pulike Biological Engineering Recent Developments/Updates
2.7 Guangdong WINSUN Bio-pharmaceutical
2.7.1 Guangdong WINSUN Bio-pharmaceutical Details
2.7.2 Guangdong WINSUN Bio-pharmaceutical Major Business
2.7.3 Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
2.7.4 Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Guangdong WINSUN Bio-pharmaceutical Recent Developments/Updates
2.8 Sinovetah Biological Pharmaceutical
2.8.1 Sinovetah Biological Pharmaceutical Details
2.8.2 Sinovetah Biological Pharmaceutical Major Business
2.8.3 Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
2.8.4 Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Sinovetah Biological Pharmaceutical Recent Developments/Updates
2.9 TECON Pharmaceutical
2.9.1 TECON Pharmaceutical Details
2.9.2 TECON Pharmaceutical Major Business
2.9.3 TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
2.9.4 TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 TECON Pharmaceutical Recent Developments/Updates
2.10 Harbin Veken Biotechnology
2.10.1 Harbin Veken Biotechnology Details
2.10.2 Harbin Veken Biotechnology Major Business
2.10.3 Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
2.10.4 Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Harbin Veken Biotechnology Recent Developments/Updates
2.11 CAHIC
2.11.1 CAHIC Details
2.11.2 CAHIC Major Business
2.11.3 CAHIC Highly Pathogenic PRRS Live Vaccine Product and Services
2.11.4 CAHIC Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.11.5 CAHIC Recent Developments/Updates
2.12 Huapai Biotechnology Group
2.12.1 Huapai Biotechnology Group Details
2.12.2 Huapai Biotechnology Group Major Business
2.12.3 Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Product and Services
2.12.4 Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.12.5 Huapai Biotechnology Group Recent Developments/Updates
2.13 Chengdu Shiji Biological Pharmaceutical
2.13.1 Chengdu Shiji Biological Pharmaceutical Details
2.13.2 Chengdu Shiji Biological Pharmaceutical Major Business
2.13.3 Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
2.13.4 Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.13.5 Chengdu Shiji Biological Pharmaceutical Recent Developments/Updates
2.14 Jilin Heyuan Biotechnology
2.14.1 Jilin Heyuan Biotechnology Details
2.14.2 Jilin Heyuan Biotechnology Major Business
2.14.3 Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
2.14.4 Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
2.14.5 Jilin Heyuan Biotechnology Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: HIGHLY PATHOGENIC PRRS LIVE VACCINE BY MANUFACTURER
3.1 Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Manufacturer (2021-2026)
3.2 Global Highly Pathogenic PRRS Live Vaccine Revenue by Manufacturer (2021-2026)
3.3 Global Highly Pathogenic PRRS Live Vaccine Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
3.4.1 Producer Shipments of Highly Pathogenic PRRS Live Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2025
3.4.2 Top 3 Highly Pathogenic PRRS Live Vaccine Manufacturer Market Share in 2025
3.4.3 Top 6 Highly Pathogenic PRRS Live Vaccine Manufacturer Market Share in 2025
3.5 Highly Pathogenic PRRS Live Vaccine Market: Overall Company Footprint Analysis
3.5.1 Highly Pathogenic PRRS Live Vaccine Market: Region Footprint
3.5.2 Highly Pathogenic PRRS Live Vaccine Market: Company Product Type Footprint
3.5.3 Highly Pathogenic PRRS Live Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Highly Pathogenic PRRS Live Vaccine Market Size by Region
4.1.1 Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Region (2021-2032)
4.1.2 Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Region (2021-2032)
4.1.3 Global Highly Pathogenic PRRS Live Vaccine Average Price by Region (2021-2032)
4.2 North America Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032)
4.3 Europe Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032)
4.4 Asia-Pacific Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032)
4.5 South America Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032)
4.6 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032)
5 MARKET SEGMENT BY TYPE
5.1 Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2032)
5.2 Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Type (2021-2032)
5.3 Global Highly Pathogenic PRRS Live Vaccine Average Price by Type (2021-2032)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2032)
6.2 Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Application (2021-2032)
6.3 Global Highly Pathogenic PRRS Live Vaccine Average Price by Application (2021-2032)
7 NORTH AMERICA
7.1 North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2032)
7.2 North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2032)
7.3 North America Highly Pathogenic PRRS Live Vaccine Market Size by Country
7.3.1 North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2021-2032)
7.3.2 North America Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2021-2032)
7.3.3 United States Market Size and Forecast (2021-2032)
7.3.4 Canada Market Size and Forecast (2021-2032)
7.3.5 Mexico Market Size and Forecast (2021-2032)
8 EUROPE
8.1 Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2032)
8.2 Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2032)
8.3 Europe Highly Pathogenic PRRS Live Vaccine Market Size by Country
8.3.1 Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2021-2032)
8.3.2 Europe Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2021-2032)
8.3.3 Germany Market Size and Forecast (2021-2032)
8.3.4 France Market Size and Forecast (2021-2032)
8.3.5 United Kingdom Market Size and Forecast (2021-2032)
8.3.6 Russia Market Size and Forecast (2021-2032)
8.3.7 Italy Market Size and Forecast (2021-2032)
9 ASIA-PACIFIC
9.1 Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Highly Pathogenic PRRS Live Vaccine Market Size by Region
9.3.1 Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Region (2021-2032)
9.3.2 Asia-Pacific Highly Pathogenic PRRS Live Vaccine Consumption Value by Region (2021-2032)
9.3.3 China Market Size and Forecast (2021-2032)
9.3.4 Japan Market Size and Forecast (2021-2032)
9.3.5 South Korea Market Size and Forecast (2021-2032)
9.3.6 India Market Size and Forecast (2021-2032)
9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
9.3.8 Australia Market Size and Forecast (2021-2032)
10 SOUTH AMERICA
10.1 South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2032)
10.2 South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2032)
10.3 South America Highly Pathogenic PRRS Live Vaccine Market Size by Country
10.3.1 South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2021-2032)
10.3.2 South America Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2021-2032)
10.3.3 Brazil Market Size and Forecast (2021-2032)
10.3.4 Argentina Market Size and Forecast (2021-2032)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Market Size by Country
11.3.1 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2021-2032)
11.3.2 Middle East & Africa Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2021-2032)
11.3.3 Turkey Market Size and Forecast (2021-2032)
11.3.4 Egypt Market Size and Forecast (2021-2032)
11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
11.3.6 South Africa Market Size and Forecast (2021-2032)
12 MARKET DYNAMICS
12.1 Highly Pathogenic PRRS Live Vaccine Market Drivers
12.2 Highly Pathogenic PRRS Live Vaccine Market Restraints
12.3 Highly Pathogenic PRRS Live Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Highly Pathogenic PRRS Live Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Highly Pathogenic PRRS Live Vaccine
13.3 Highly Pathogenic PRRS Live Vaccine Production Process
13.4 Industry Value Chain Analysis
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Highly Pathogenic PRRS Live Vaccine Typical Distributors
14.3 Highly Pathogenic PRRS Live Vaccine Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Product Combination, (USD Million), 2021 & 2025 & 2032
Table 3. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Table 4. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Dahuanong Animal Health Basic Information, Manufacturing Base and Competitors
Table 6. Dahuanong Animal Health Major Business
Table 7. Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Product and Services
Table 8. Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Dahuanong Animal Health Recent Developments/Updates
Table 10. Zoetis Basic Information, Manufacturing Base and Competitors
Table 11. Zoetis Major Business
Table 12. Zoetis Highly Pathogenic PRRS Live Vaccine Product and Services
Table 13. Zoetis Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Zoetis Recent Developments/Updates
Table 15. Jilin Teyan Biotechnology Basic Information, Manufacturing Base and Competitors
Table 16. Jilin Teyan Biotechnology Major Business
Table 17. Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
Table 18. Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Jilin Teyan Biotechnology Recent Developments/Updates
Table 20. Qingdao Yebio Bioengineering Basic Information, Manufacturing Base and Competitors
Table 21. Qingdao Yebio Bioengineering Major Business
Table 22. Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Product and Services
Table 23. Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 24. Qingdao Yebio Bioengineering Recent Developments/Updates
Table 25. Sinopharm Yangzhou Vac Biological Engineering Basic Information, Manufacturing Base and Competitors
Table 26. Sinopharm Yangzhou Vac Biological Engineering Major Business
Table 27. Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Product and Services
Table 28. Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 29. Sinopharm Yangzhou Vac Biological Engineering Recent Developments/Updates
Table 30. Pulike Biological Engineering Basic Information, Manufacturing Base and Competitors
Table 31. Pulike Biological Engineering Major Business
Table 32. Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Product and Services
Table 33. Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 34. Pulike Biological Engineering Recent Developments/Updates
Table 35. Guangdong WINSUN Bio-pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 36. Guangdong WINSUN Bio-pharmaceutical Major Business
Table 37. Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
Table 38. Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 39. Guangdong WINSUN Bio-pharmaceutical Recent Developments/Updates
Table 40. Sinovetah Biological Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 41. Sinovetah Biological Pharmaceutical Major Business
Table 42. Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
Table 43. Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 44. Sinovetah Biological Pharmaceutical Recent Developments/Updates
Table 45. TECON Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 46. TECON Pharmaceutical Major Business
Table 47. TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
Table 48. TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 49. TECON Pharmaceutical Recent Developments/Updates
Table 50. Harbin Veken Biotechnology Basic Information, Manufacturing Base and Competitors
Table 51. Harbin Veken Biotechnology Major Business
Table 52. Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
Table 53. Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 54. Harbin Veken Biotechnology Recent Developments/Updates
Table 55. CAHIC Basic Information, Manufacturing Base and Competitors
Table 56. CAHIC Major Business
Table 57. CAHIC Highly Pathogenic PRRS Live Vaccine Product and Services
Table 58. CAHIC Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 59. CAHIC Recent Developments/Updates
Table 60. Huapai Biotechnology Group Basic Information, Manufacturing Base and Competitors
Table 61. Huapai Biotechnology Group Major Business
Table 62. Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Product and Services
Table 63. Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 64. Huapai Biotechnology Group Recent Developments/Updates
Table 65. Chengdu Shiji Biological Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 66. Chengdu Shiji Biological Pharmaceutical Major Business
Table 67. Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
Table 68. Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 69. Chengdu Shiji Biological Pharmaceutical Recent Developments/Updates
Table 70. Jilin Heyuan Biotechnology Basic Information, Manufacturing Base and Competitors
Table 71. Jilin Heyuan Biotechnology Major Business
Table 72. Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
Table 73. Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 74. Jilin Heyuan Biotechnology Recent Developments/Updates
Table 75. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Manufacturer (2021-2026) & (K Dose)
Table 76. Global Highly Pathogenic PRRS Live Vaccine Revenue by Manufacturer (2021-2026) & (USD Million)
Table 77. Global Highly Pathogenic PRRS Live Vaccine Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 78. Market Position of Manufacturers in Highly Pathogenic PRRS Live Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 79. Head Office and Highly Pathogenic PRRS Live Vaccine Production Site of Key Manufacturer
Table 80. Highly Pathogenic PRRS Live Vaccine Market: Company Product Type Footprint
Table 81. Highly Pathogenic PRRS Live Vaccine Market: Company Product Application Footprint
Table 82. Highly Pathogenic PRRS Live Vaccine New Market Entrants and Barriers to Market Entry
Table 83. Highly Pathogenic PRRS Live Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 84. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 85. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Region (2021-2026) & (K Dose)
Table 86. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Region (2027-2032) & (K Dose)
Table 87. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 88. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Region (2027-2032) & (USD Million)
Table 89. Global Highly Pathogenic PRRS Live Vaccine Average Price by Region (2021-2026) & (US$/Dose)
Table 90. Global Highly Pathogenic PRRS Live Vaccine Average Price by Region (2027-2032) & (US$/Dose)
Table 91. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 92. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 93. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Type (2021-2026) & (USD Million)
Table 94. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Type (2027-2032) & (USD Million)
Table 95. Global Highly Pathogenic PRRS Live Vaccine Average Price by Type (2021-2026) & (US$/Dose)
Table 96. Global Highly Pathogenic PRRS Live Vaccine Average Price by Type (2027-2032) & (US$/Dose)
Table 97. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 98. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 99. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Application (2021-2026) & (USD Million)
Table 100. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Application (2027-2032) & (USD Million)
Table 101. Global Highly Pathogenic PRRS Live Vaccine Average Price by Application (2021-2026) & (US$/Dose)
Table 102. Global Highly Pathogenic PRRS Live Vaccine Average Price by Application (2027-2032) & (US$/Dose)
Table 103. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 104. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 105. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 106. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 107. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 108. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 109. North America Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 110. North America Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 111. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 112. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 113. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 114. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 115. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 116. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 117. Europe Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 118. Europe Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 119. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 120. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 121. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 122. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 123. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Region (2021-2026) & (K Dose)
Table 124. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Region (2027-2032) & (K Dose)
Table 125. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 126. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Consumption Value by Region (2027-2032) & (USD Million)
Table 127. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 128. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 129. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 130. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 131. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 132. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 133. South America Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 134. South America Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 135. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 136. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 137. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 138. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 139. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 140. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 141. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 142. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 143. Highly Pathogenic PRRS Live Vaccine Raw Material
Table 144. Key Manufacturers of Highly Pathogenic PRRS Live Vaccine Raw Materials
Table 145. Highly Pathogenic PRRS Live Vaccine Typical Distributors
Table 146. Highly Pathogenic PRRS Live Vaccine Typical Customers
Table 1. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Product Combination, (USD Million), 2021 & 2025 & 2032
Table 3. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Table 4. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Dahuanong Animal Health Basic Information, Manufacturing Base and Competitors
Table 6. Dahuanong Animal Health Major Business
Table 7. Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Product and Services
Table 8. Dahuanong Animal Health Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 9. Dahuanong Animal Health Recent Developments/Updates
Table 10. Zoetis Basic Information, Manufacturing Base and Competitors
Table 11. Zoetis Major Business
Table 12. Zoetis Highly Pathogenic PRRS Live Vaccine Product and Services
Table 13. Zoetis Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 14. Zoetis Recent Developments/Updates
Table 15. Jilin Teyan Biotechnology Basic Information, Manufacturing Base and Competitors
Table 16. Jilin Teyan Biotechnology Major Business
Table 17. Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
Table 18. Jilin Teyan Biotechnology Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 19. Jilin Teyan Biotechnology Recent Developments/Updates
Table 20. Qingdao Yebio Bioengineering Basic Information, Manufacturing Base and Competitors
Table 21. Qingdao Yebio Bioengineering Major Business
Table 22. Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Product and Services
Table 23. Qingdao Yebio Bioengineering Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 24. Qingdao Yebio Bioengineering Recent Developments/Updates
Table 25. Sinopharm Yangzhou Vac Biological Engineering Basic Information, Manufacturing Base and Competitors
Table 26. Sinopharm Yangzhou Vac Biological Engineering Major Business
Table 27. Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Product and Services
Table 28. Sinopharm Yangzhou Vac Biological Engineering Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 29. Sinopharm Yangzhou Vac Biological Engineering Recent Developments/Updates
Table 30. Pulike Biological Engineering Basic Information, Manufacturing Base and Competitors
Table 31. Pulike Biological Engineering Major Business
Table 32. Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Product and Services
Table 33. Pulike Biological Engineering Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 34. Pulike Biological Engineering Recent Developments/Updates
Table 35. Guangdong WINSUN Bio-pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 36. Guangdong WINSUN Bio-pharmaceutical Major Business
Table 37. Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
Table 38. Guangdong WINSUN Bio-pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 39. Guangdong WINSUN Bio-pharmaceutical Recent Developments/Updates
Table 40. Sinovetah Biological Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 41. Sinovetah Biological Pharmaceutical Major Business
Table 42. Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
Table 43. Sinovetah Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 44. Sinovetah Biological Pharmaceutical Recent Developments/Updates
Table 45. TECON Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 46. TECON Pharmaceutical Major Business
Table 47. TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
Table 48. TECON Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 49. TECON Pharmaceutical Recent Developments/Updates
Table 50. Harbin Veken Biotechnology Basic Information, Manufacturing Base and Competitors
Table 51. Harbin Veken Biotechnology Major Business
Table 52. Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
Table 53. Harbin Veken Biotechnology Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 54. Harbin Veken Biotechnology Recent Developments/Updates
Table 55. CAHIC Basic Information, Manufacturing Base and Competitors
Table 56. CAHIC Major Business
Table 57. CAHIC Highly Pathogenic PRRS Live Vaccine Product and Services
Table 58. CAHIC Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 59. CAHIC Recent Developments/Updates
Table 60. Huapai Biotechnology Group Basic Information, Manufacturing Base and Competitors
Table 61. Huapai Biotechnology Group Major Business
Table 62. Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Product and Services
Table 63. Huapai Biotechnology Group Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 64. Huapai Biotechnology Group Recent Developments/Updates
Table 65. Chengdu Shiji Biological Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 66. Chengdu Shiji Biological Pharmaceutical Major Business
Table 67. Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Product and Services
Table 68. Chengdu Shiji Biological Pharmaceutical Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 69. Chengdu Shiji Biological Pharmaceutical Recent Developments/Updates
Table 70. Jilin Heyuan Biotechnology Basic Information, Manufacturing Base and Competitors
Table 71. Jilin Heyuan Biotechnology Major Business
Table 72. Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Product and Services
Table 73. Jilin Heyuan Biotechnology Highly Pathogenic PRRS Live Vaccine Sales Quantity (K Dose), Average Price (US$/Dose), Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 74. Jilin Heyuan Biotechnology Recent Developments/Updates
Table 75. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Manufacturer (2021-2026) & (K Dose)
Table 76. Global Highly Pathogenic PRRS Live Vaccine Revenue by Manufacturer (2021-2026) & (USD Million)
Table 77. Global Highly Pathogenic PRRS Live Vaccine Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 78. Market Position of Manufacturers in Highly Pathogenic PRRS Live Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 79. Head Office and Highly Pathogenic PRRS Live Vaccine Production Site of Key Manufacturer
Table 80. Highly Pathogenic PRRS Live Vaccine Market: Company Product Type Footprint
Table 81. Highly Pathogenic PRRS Live Vaccine Market: Company Product Application Footprint
Table 82. Highly Pathogenic PRRS Live Vaccine New Market Entrants and Barriers to Market Entry
Table 83. Highly Pathogenic PRRS Live Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 84. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR
Table 85. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Region (2021-2026) & (K Dose)
Table 86. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Region (2027-2032) & (K Dose)
Table 87. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 88. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Region (2027-2032) & (USD Million)
Table 89. Global Highly Pathogenic PRRS Live Vaccine Average Price by Region (2021-2026) & (US$/Dose)
Table 90. Global Highly Pathogenic PRRS Live Vaccine Average Price by Region (2027-2032) & (US$/Dose)
Table 91. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 92. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 93. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Type (2021-2026) & (USD Million)
Table 94. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Type (2027-2032) & (USD Million)
Table 95. Global Highly Pathogenic PRRS Live Vaccine Average Price by Type (2021-2026) & (US$/Dose)
Table 96. Global Highly Pathogenic PRRS Live Vaccine Average Price by Type (2027-2032) & (US$/Dose)
Table 97. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 98. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 99. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Application (2021-2026) & (USD Million)
Table 100. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Application (2027-2032) & (USD Million)
Table 101. Global Highly Pathogenic PRRS Live Vaccine Average Price by Application (2021-2026) & (US$/Dose)
Table 102. Global Highly Pathogenic PRRS Live Vaccine Average Price by Application (2027-2032) & (US$/Dose)
Table 103. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 104. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 105. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 106. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 107. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 108. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 109. North America Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 110. North America Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 111. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 112. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 113. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 114. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 115. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 116. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 117. Europe Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 118. Europe Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 119. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 120. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 121. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 122. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 123. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Region (2021-2026) & (K Dose)
Table 124. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity by Region (2027-2032) & (K Dose)
Table 125. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 126. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Consumption Value by Region (2027-2032) & (USD Million)
Table 127. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 128. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 129. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 130. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 131. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 132. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 133. South America Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 134. South America Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 135. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2021-2026) & (K Dose)
Table 136. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Type (2027-2032) & (K Dose)
Table 137. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2021-2026) & (K Dose)
Table 138. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Application (2027-2032) & (K Dose)
Table 139. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2021-2026) & (K Dose)
Table 140. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity by Country (2027-2032) & (K Dose)
Table 141. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2021-2026) & (USD Million)
Table 142. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Consumption Value by Country (2027-2032) & (USD Million)
Table 143. Highly Pathogenic PRRS Live Vaccine Raw Material
Table 144. Key Manufacturers of Highly Pathogenic PRRS Live Vaccine Raw Materials
Table 145. Highly Pathogenic PRRS Live Vaccine Typical Distributors
Table 146. Highly Pathogenic PRRS Live Vaccine Typical Customers
LIST OF FIGURES
Figure 1. Highly Pathogenic PRRS Live Vaccine Picture
Figure 2. Global Highly Pathogenic PRRS Live Vaccine Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Type in 2025
Figure 4. JXA1-R Strain Live Vaccine Examples
Figure 5. TJM-F92 Strain Live Vaccine Examples
Figure 6. GDr180 Strain Live Vaccine Examples
Figure 7. Others Examples
Figure 8. Global Highly Pathogenic PRRS Live Vaccine Revenue by Product Combination, (USD Million), 2021 & 2025 & 2032
Figure 9. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Product Combination in 2025
Figure 10. Monovalent Live Vaccine Examples
Figure 11. Combination Live Vaccine Examples
Figure 12. Global Highly Pathogenic PRRS Live Vaccine Revenue by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Figure 13. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Dose Pack Size in 2025
Figure 14. Small Pack (Below 20 Doses per Vial) Examples
Figure 15. Medium Pack (20–50 Doses per Vial) Examples
Figure 16. Large Pack (Above 50 Doses per Vial) Examples
Figure 17. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 18. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Application in 2025
Figure 19. Large-scale Integrated Pig Farming Groups Examples
Figure 20. Breeding and Multiplier Farms Examples
Figure 21. Animal Disease Control Institutions Examples
Figure 22. Others Examples
Figure 23. Global Highly Pathogenic PRRS Live Vaccine Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 24. Global Highly Pathogenic PRRS Live Vaccine Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 25. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity (2021-2032) & (K Dose)
Figure 26. Global Highly Pathogenic PRRS Live Vaccine Price (2021-2032) & (US$/Dose)
Figure 27. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Manufacturer in 2025
Figure 28. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Manufacturer in 2025
Figure 29. Producer Shipments of Highly Pathogenic PRRS Live Vaccine by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 30. Top 3 Highly Pathogenic PRRS Live Vaccine Manufacturer (Revenue) Market Share in 2025
Figure 31. Top 6 Highly Pathogenic PRRS Live Vaccine Manufacturer (Revenue) Market Share in 2025
Figure 32. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Region (2021-2032)
Figure 33. Global Highly Pathogenic PRRS Live Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 34. North America Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 35. Europe Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 36. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 37. South America Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 38. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 39. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 40. Global Highly Pathogenic PRRS Live Vaccine Consumption Value Market Share by Type (2021-2032)
Figure 41. Global Highly Pathogenic PRRS Live Vaccine Average Price by Type (2021-2032) & (US$/Dose)
Figure 42. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 43. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Application (2021-2032)
Figure 44. Global Highly Pathogenic PRRS Live Vaccine Average Price by Application (2021-2032) & (US$/Dose)
Figure 45. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 46. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 47. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 48. North America Highly Pathogenic PRRS Live Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 49. United States Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 50. Canada Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 51. Mexico Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 52. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 53. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 54. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 55. Europe Highly Pathogenic PRRS Live Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 56. Germany Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 57. France Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 58. United Kingdom Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 59. Russia Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 60. Italy Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 61. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 62. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 63. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Region (2021-2032)
Figure 64. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 65. China Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 66. Japan Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 67. South Korea Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 68. India Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 69. Southeast Asia Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 70. Australia Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 71. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 72. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 73. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 74. South America Highly Pathogenic PRRS Live Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 75. Brazil Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 76. Argentina Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 77. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 78. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 79. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 80. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 81. Turkey Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 82. Egypt Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 83. Saudi Arabia Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 84. South Africa Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 85. Highly Pathogenic PRRS Live Vaccine Market Drivers
Figure 86. Highly Pathogenic PRRS Live Vaccine Market Restraints
Figure 87. Highly Pathogenic PRRS Live Vaccine Market Trends
Figure 88. Porters Five Forces Analysis
Figure 89. Manufacturing Cost Structure Analysis of Highly Pathogenic PRRS Live Vaccine in 2025
Figure 90. Manufacturing Process Analysis of Highly Pathogenic PRRS Live Vaccine
Figure 91. Highly Pathogenic PRRS Live Vaccine Industrial Chain
Figure 92. Sales Channel: Direct to End-User vs Distributors
Figure 93. Direct Channel Pros & Cons
Figure 94. Indirect Channel Pros & Cons
Figure 95. Methodology
Figure 96. Research Process and Data Source
Figure 1. Highly Pathogenic PRRS Live Vaccine Picture
Figure 2. Global Highly Pathogenic PRRS Live Vaccine Revenue by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Type in 2025
Figure 4. JXA1-R Strain Live Vaccine Examples
Figure 5. TJM-F92 Strain Live Vaccine Examples
Figure 6. GDr180 Strain Live Vaccine Examples
Figure 7. Others Examples
Figure 8. Global Highly Pathogenic PRRS Live Vaccine Revenue by Product Combination, (USD Million), 2021 & 2025 & 2032
Figure 9. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Product Combination in 2025
Figure 10. Monovalent Live Vaccine Examples
Figure 11. Combination Live Vaccine Examples
Figure 12. Global Highly Pathogenic PRRS Live Vaccine Revenue by Dose Pack Size, (USD Million), 2021 & 2025 & 2032
Figure 13. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Dose Pack Size in 2025
Figure 14. Small Pack (Below 20 Doses per Vial) Examples
Figure 15. Medium Pack (20–50 Doses per Vial) Examples
Figure 16. Large Pack (Above 50 Doses per Vial) Examples
Figure 17. Global Highly Pathogenic PRRS Live Vaccine Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 18. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Application in 2025
Figure 19. Large-scale Integrated Pig Farming Groups Examples
Figure 20. Breeding and Multiplier Farms Examples
Figure 21. Animal Disease Control Institutions Examples
Figure 22. Others Examples
Figure 23. Global Highly Pathogenic PRRS Live Vaccine Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 24. Global Highly Pathogenic PRRS Live Vaccine Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 25. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity (2021-2032) & (K Dose)
Figure 26. Global Highly Pathogenic PRRS Live Vaccine Price (2021-2032) & (US$/Dose)
Figure 27. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Manufacturer in 2025
Figure 28. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Manufacturer in 2025
Figure 29. Producer Shipments of Highly Pathogenic PRRS Live Vaccine by Manufacturer Sales ($MM) and Market Share (%): 2025
Figure 30. Top 3 Highly Pathogenic PRRS Live Vaccine Manufacturer (Revenue) Market Share in 2025
Figure 31. Top 6 Highly Pathogenic PRRS Live Vaccine Manufacturer (Revenue) Market Share in 2025
Figure 32. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Region (2021-2032)
Figure 33. Global Highly Pathogenic PRRS Live Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 34. North America Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 35. Europe Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 36. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 37. South America Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 38. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 39. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 40. Global Highly Pathogenic PRRS Live Vaccine Consumption Value Market Share by Type (2021-2032)
Figure 41. Global Highly Pathogenic PRRS Live Vaccine Average Price by Type (2021-2032) & (US$/Dose)
Figure 42. Global Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 43. Global Highly Pathogenic PRRS Live Vaccine Revenue Market Share by Application (2021-2032)
Figure 44. Global Highly Pathogenic PRRS Live Vaccine Average Price by Application (2021-2032) & (US$/Dose)
Figure 45. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 46. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 47. North America Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 48. North America Highly Pathogenic PRRS Live Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 49. United States Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 50. Canada Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 51. Mexico Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 52. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 53. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 54. Europe Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 55. Europe Highly Pathogenic PRRS Live Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 56. Germany Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 57. France Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 58. United Kingdom Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 59. Russia Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 60. Italy Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 61. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 62. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 63. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Region (2021-2032)
Figure 64. Asia-Pacific Highly Pathogenic PRRS Live Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 65. China Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 66. Japan Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 67. South Korea Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 68. India Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 69. Southeast Asia Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 70. Australia Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 71. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 72. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 73. South America Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 74. South America Highly Pathogenic PRRS Live Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 75. Brazil Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 76. Argentina Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 77. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Type (2021-2032)
Figure 78. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Application (2021-2032)
Figure 79. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Sales Quantity Market Share by Country (2021-2032)
Figure 80. Middle East & Africa Highly Pathogenic PRRS Live Vaccine Consumption Value Market Share by Country (2021-2032)
Figure 81. Turkey Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 82. Egypt Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 83. Saudi Arabia Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 84. South Africa Highly Pathogenic PRRS Live Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 85. Highly Pathogenic PRRS Live Vaccine Market Drivers
Figure 86. Highly Pathogenic PRRS Live Vaccine Market Restraints
Figure 87. Highly Pathogenic PRRS Live Vaccine Market Trends
Figure 88. Porters Five Forces Analysis
Figure 89. Manufacturing Cost Structure Analysis of Highly Pathogenic PRRS Live Vaccine in 2025
Figure 90. Manufacturing Process Analysis of Highly Pathogenic PRRS Live Vaccine
Figure 91. Highly Pathogenic PRRS Live Vaccine Industrial Chain
Figure 92. Sales Channel: Direct to End-User vs Distributors
Figure 93. Direct Channel Pros & Cons
Figure 94. Indirect Channel Pros & Cons
Figure 95. Methodology
Figure 96. Research Process and Data Source
